Sub sections

Bookmark and Share

Point
Time to Let the FDA Process Go Forward

By Bruce Mirken
Director of Communications Marijuana Policy Project

The reason that marijuana is not presently an FDA-approved medicine is clear: The federal government has systematically blocked the type of research that would be needed for the agency to consider licensing marijuana as a prescription drug.

The recorded medicinal use of this remarkably versatile plant goes back thousands of years [1]  In recent years, modern clinical trials have found that it stimulates appetite and improves sleep in HIV/AIDS patients[2] and relieves neuropathic pain associated with HIV disease [3], even when the pain is refractory to other medications [4]. It has also been shown effective at treating neuropathic pain from other causes [5]. In all of these trials, toxicities have been mild and serious adverse events have been rare.

What we don’t have -- and never will have until federal anti-drug bureaucrats get out of the way -- is the type of research needed to put together an FDA new drug application. The reason for this is that, unlike any other drug – even other Schedule I drugs – the federal government retains absolute control of the supply of marijuana that can be used for research. Researchers are required to obtain marijuana for clinical research from the National Institute on Drug Abuse, which contracts with the University of Mississippi to run the only legal source of research marijuana in the U.S. [6].

But that Mississippi marijuana is only available for research, not for prescription sale, meaning any researcher seeking to develop marijuana as a prescription drug can never test precisely the same product they’d be selling. And if they want to develop particular strains with varying ratios of cannabinoids (the 80+ unique, active components in marijuana) to test for different ailments – well, forget it.

Professor Lyle Craker at the University of Massachusetts Amherst has been attempting to set up a production facility to solve these problems. In 2005, 38 members of Congress wrote to the Drug Enforcement Administration [7] to urge the DEA to allow Craker to proceed. They called the NIDA monopoly on marijuana for research “unjustified,” explaining, “The licensing of Prof. Craker’s facility would provide privately-funded sponsors of FDA-approved research the necessary opportunity to conduct studies with a strain of their own choosing, with access to that strain for all FDA-approved studies and for possible prescription use. None of this is possible under NIDA’s monopoly.”

Four years later and despite an administrative law judge ruling [8] in Craker’s favor, the DEA is still blocking Craker’s project.

It’s time for the drug war bureaucracy to get out of the way and permit medical marijuana research aimed at securing FDA approval.

References:

1. http://www3.interscience.wiley.com/journal/115806128/abstract
2. http://journals.lww.com/jaids/Fulltext/2007/08150/Dronabinol_and_Marijuana_in_HIV_Positive_Marijuana.9.aspx
3. http://www.neurology.org/cgi/content/abstract/68/7/515 
4. http://www.nature.com/npp/journal/v34/n3/abs/npp2008120a.html
5. http://www.jpain.org/article/S1526-5900(08)00369-6/abstract
6. http://edition.cnn.com/2009/CRIME/05/18/government.marijuana.garden/
7. http://www.maps.org/mmj/congressletter.pdf
8. http://www.maps.org/ALJfindings.PDF  

→Return

→Read the Counterpoint to this opinion

Visit the Marijuana Policy Project online at:

http://www.mpp.org

info@mpp.org

Contact Mr. Mirken of the Marijuana Policy Project at:

Marijuana Policy Project
236 Massachusetts Ave. NE, Suite 400
Washington, D.C. 20002
202-462-5747
media@mpp.org